How can we differentiate between immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), and hemolytic‑uremic syndrome (HUS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Differentiating ITP, TTP, and HUS

The key to differentiating these three thrombotic microangiopathies is ADAMTS-13 testing: severe deficiency (<10%) confirms TTP, while normal levels point to HUS or ITP, which are then distinguished by the presence or absence of microangiopathic hemolytic anemia (MAHA).

Diagnostic Algorithm

Step 1: Assess for Microangiopathic Hemolytic Anemia (MAHA)

ITP presents with:

  • Isolated thrombocytopenia (often <30 × 10⁹/L)
  • NO hemolysis - normal hemoglobin, normal LDH, no schistocytes on blood smear
  • Normal renal function
  • Diagnosis of exclusion 1

TTP and HUS both present with:

  • Thrombocytopenia (usually <30 × 10⁹/L) 2
  • MAHA present - low hemoglobin, elevated LDH, schistocytes on peripheral smear
  • Variable organ damage 2

Step 2: Measure ADAMTS-13 Activity (Critical Test)

TTP is confirmed by:

  • ADAMTS-13 activity <10% (or <10 IU/dL) 2
  • Positive anti-ADAMTS-13 IgG antibodies in immune TTP (iTTP) 2
  • Note: Antibodies may be negative initially in acute iTTP due to antibody-ADAMTS-13 complex clearance 2
  • Genetic testing for ADAMTS13 mutations confirms congenital TTP (cTTP) 2

HUS shows:

  • Normal or mildly reduced ADAMTS-13 activity (>10%) 3, 4
  • Complement dysregulation in atypical HUS 3

Step 3: Clinical Context and Organ Involvement

TTP predominantly affects:

  • Neurological system - confusion, altered mental status, seizures, focal deficits 2
  • Cardiac involvement 5
  • Renal involvement can occur but less prominent 5

HUS predominantly affects:

  • Kidneys - acute kidney injury, elevated creatinine, hematuria 3, 5
  • Typical (STEC-HUS): preceded by bloody diarrhea from Shiga-toxin producing E. coli 3
  • Atypical HUS: no diarrhea prodrome, complement-mediated 3

ITP shows:

  • Bleeding manifestations - petechiae, bruising, mucosal bleeding
  • No organ ischemia or dysfunction
  • Intracranial hemorrhage rare (1.4% adults, 0.1-0.4% children) 1

Practical Clinical Scoring

While awaiting ADAMTS-13 results, use clinical scoring systems:

  • French score or PLASMIC score to assess likelihood of severe ADAMTS-13 deficiency 2
  • Simple predictors: platelet count and serum creatinine can predict ADAMTS-13 deficiency with good accuracy 3

Additional Distinguishing Tests

Red blood cell lifespan (RBCLS) via carbon monoxide breath test:

  • TTP: markedly shortened (mean 20 ± 8 days)
  • ITP with anemia: normal to mildly reduced (77 ± 22 days)
  • Cut-off of 32 days has 95.7% sensitivity and 96.9% specificity for TTP 6

Critical Management Implications

Start plasma exchange immediately when TTP is suspected based on thrombocytopenia + MAHA + schistocytes, even before ADAMTS-13 results return 7, 8. Do not delay treatment.

ITP requires corticosteroids or observation depending on bleeding severity and platelet count 1.

Atypical HUS responds to eculizumab (complement inhibitor), not plasma exchange 3, 4.

Common Pitfalls

  • Do not rely solely on organ involvement patterns - TTP can have renal involvement and HUS can have neurological symptoms; there is significant overlap 4, 9
  • Do not withhold plasma exchange while waiting for ADAMTS-13 results if TTP is suspected clinically 4
  • Do not assume negative anti-ADAMTS-13 antibodies rule out iTTP during acute episodes - repeat testing after treatment 2
  • Exclude gastrointestinal bleeding when using RBCLS testing, as it reduces diagnostic accuracy to 93% 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.